Skip to content

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05912972
Enrollment
13500
Registered
2023-06-22
Start date
2022-10-21
Completion date
2027-10-21
Last updated
2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Brief summary

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates.

Detailed description

Cervical cancer, endometrial cancer, and ovarian cancer represent gynecologic cancers. There are many open issues that need to be addressed, specifically the surgical method, disease recurrence and survival outcome in the so called real world setting. The aim of this observational study is to collect both retrospective and prospective medical information of gynecologic cancer patients.

Interventions

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female patients 18 years or older * Written informed consent (prospective cohort) * Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Exclusion criteria

* Unconfirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Design outcomes

Primary

MeasureTime frameDescription
Overall survival5 yearsAnalyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to baseline characteristics, surgical methods, and treatment

Secondary

MeasureTime frameDescription
Progression-free survival5 yearsAnalyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to baseline characteristics, surgical methods, and treatment

Countries

South Korea

Contacts

Primary ContactJeong-Yeol Park, PhD
obgyjypark@amc.seoul.kr+82230103646
Backup ContactSo Hyun Nam, MD
gynamsh@gmail.com+82230100869

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026